Biodexa pharmaceuticals plc investigated regarding potential securities law violations - contact levi & korsinsky for details - bdrx

New york, ny / accesswire / october 21, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of biodexa pharmaceuticals plc ("biodexa pharmaceuticals plc") (nasdaq:bdrx) concerning possible violations of federal securities laws. on october 4, 2024, biodexa reported updated data on progression-free and overall survival from a phase 1 study of its drug mx110 in the treatment of recurrent glioblastoma.
BDRX Ratings Summary
BDRX Quant Ranking